Paper39384196
Novel H-2Db-restricted CD8 epitope derived from mouse MAGE-type antigen P1A mediates antitumor immunity in C57BL/6 mice.
McAuliffe J and 15 others. J Immunother Cancer, 2024. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Novel H-2Db-restricted CD8 epitope derived from mouse MAGE-type antigen P1A mediates antitumor immunity in C57BL/6 mice. Papers, record 39384196. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39384196
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Novel H-2Db-restricted CD8 epitope derived from mouse MAGE-type antigen P1A mediates antitumor immunity in C57BL/6 mice.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Epitopes, T-Lymphocyte | Major topic |
| CD8-Positive T-Lymphocytes | Major topic |
| Mice, Inbred C57BL | Major topic |
| Cancer Vaccines | Major topic |
| Animals | |
| Mice | |
| Female | |
| Antigens, Neoplasm | |
| Histocompatibility Antigen H-2D | |
| Cell Line, Tumor | |
| H-2 Antigens |
Source PubMed
References35
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30356111 | Combination of immune checkpoint blockade with DNA cancer vaccine induces potent antitumor immunity against P815 mastocytoma. | Sci Rep | 2018 | https://conductscience.org/library/papers/30356111 | PubMed |
| 2 | 21282551 | Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. | J Clin Oncol | 2011 | https://conductscience.org/library/papers/21282551 | PubMed |
| 3 | 25538264 | A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. | Clin Cancer Res | 2015 | https://conductscience.org/library/papers/25538264 | PubMed |
| 4 | 29122757 | CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells. | Blood | 2018 | https://conductscience.org/library/papers/29122757 | PubMed |
| 5 | 22949370 | Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies. | Eur J Immunol | 2012 | https://conductscience.org/library/papers/22949370 | PubMed |
| 6 | 30635236 | Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1-CD8+ Tumor-Infiltrating T Cells. | Immunity | 2019 | https://conductscience.org/library/papers/30635236 | PubMed |
| 7 | 1903428 | The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. | J Exp Med | 1991 | https://conductscience.org/library/papers/1903428 | PubMed |
| 8 | 16424047 | De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model. | Cancer Res | 2006 | https://conductscience.org/library/papers/16424047 | PubMed |
| 9 | 35159231 | Functional Differences between Proteasome Subtypes. | Cells | 2022 | https://conductscience.org/library/papers/35159231 | PubMed |
| 10 | 35452075 | High-efficiency nonviral CRISPR/Cas9-mediated gene editing of human T cells using plasmid donor DNA. | J Exp Med | 2022 | https://conductscience.org/library/papers/35452075 | PubMed |
| 11 | 32579133 | Intratumoral immune activation with TLR4 agonist synergizes with effector T cells to eradicate established murine tumors. | NPJ Vaccines | 2020 | https://conductscience.org/library/papers/32579133 | PubMed |
| 12 | 36323434 | Intravenous administration of viral vectors expressing prostate cancer antigens enhances the magnitude and functionality of CD8+ T cell responses. | J Immunother Cancer | 2022 | https://conductscience.org/library/papers/36323434 | PubMed |
| 13 | 16912204 | Different lineages of P1A-expressing cancer cells use divergent modes of immune evasion for T-cell adoptive therapy. | Cancer Res | 2006 | https://conductscience.org/library/papers/16912204 | PubMed |
| 14 | 14522934 | On the role of unmutated antigens in tumor rejection in mice with unperturbed T-cell repertoires. | Cancer Res | 2003 | https://conductscience.org/library/papers/14522934 | PubMed |
| 15 | 27533016 | T Cell Factor 1-Expressing Memory-like CD8(+) T Cells Sustain the Immune Response to Chronic Viral Infections. | Immunity | 2016 | https://conductscience.org/library/papers/27533016 | PubMed |
| 16 | 19008445 | Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. | Science | 2008 | https://conductscience.org/library/papers/19008445 | PubMed |
| 17 | 34479921 | Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy. | J Immunother Cancer | 2021 | https://conductscience.org/library/papers/34479921 | PubMed |
| 18 | 17406263 | Generation of T-cell receptor retrogenic mice. | Nat Protoc | 2006 | https://conductscience.org/library/papers/17406263 | PubMed |
| 19 | 21933959 | Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. | Proc Natl Acad Sci U S A | 2011 | https://conductscience.org/library/papers/21933959 | PubMed |
| 20 | 30573690 | A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab. | Clin Cancer Res | 2019 | https://conductscience.org/library/papers/30573690 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 41268603 | Comparative analysis of pan MHC‑I epitopes immunoreactivity on Hantaan virus nucleocapsid protein. | Int J Mol Med | 2026 | https://conductscience.org/library/papers/41268603 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39384196
GET https://conductscience.org/api/papers/v1/39384196/references?page=2